私募股权公司 Inflexion 周五表示，将把其持有的英国检测与安全合规公司 Celnor Group 的多数股权出售给高盛另类投资部门。
Private equity firm Inflexion said on Friday it would sell a majority stake in British testing and safety compliance company Celnor Group to Goldman Sachs Alternatives.
交易条款未予披露，但据知情人士透露，此次交易对 Celnor 的估值为 10 亿欧元（约合 11.2 亿美元）。Inflexion 表示将保留 Celnor 的少数股权，该公司是 Inflexion 于 2023 年协助成立的。这家欧洲私募股权公司称，Celnor 采取以收购为主导的战略，在英国获得发展势头，并向美国和欧洲扩张。该公司此前已收购美国的 John Turner Consulting 以及法国的 Tera Environnement 和 Toxilabo。
Celnor 在另一份声明中表示，其业务涵盖从石棉检测到食品安全研究等领域，高盛将支持其在美国和欧洲大陆的扩张，并增强其收购能力。高盛在接受路透社联系时拒绝置评。
Terms of the deal were not disclosed, but the deal values Celnor at €1 billion ($1.12 billion), according to a person familiar with the situation Inflexion said it will keep a minority stake in Celnor, a company it helped set up in 2023 Celnor has pursued an acquisition-led strategy, gaining momentum in the UK and expanding in the US and Europe, the European private equity firm said The company has previously acquired US-based firms such as John Turner Consulting and French firms Tera Environnement and Toxilabo Celnor, whose services span asbestos testing to food safety research, said in a separate statement that Goldman Sachs will support its expansion in the US and Continental Europe and bolster its acquisition capabilities Goldman Sachs declined to comment when contacted by Reuters